Literature DB >> 11129652

Activation of human neutrophils by the plant lectin Viscum album agglutinin-I: modulation of de novo protein synthesis and evidence that caspases are involved in induction of apoptosis.

A Savoie1, V Lavastre, M Pelletier, T Hajto, K Hostanska, D Girard.   

Abstract

The plant lectin Viscum album agglutinin-I (VAA-I) was recently found to modulate protein synthesis and to induce apoptosis in various cells of immune origin. We found that VAA-I induces de novo protein synthesis of metabolically 35S-labeled human neutrophils when used at low concentrations (< 100 ng/mL) but acts as an inhibitor at higher concentrations. Using both flow cytometry (FITC-Annexin-V/PI labeling) and cytology (Diff-Quick staining) approaches, we found that VAA-I could not modulate neutrophil apoptosis at low concentrations but could induce it in >98% of cells at 500 and 1000 ng/mL. VAA-I was also found to reverse the delaying effect of GM-CSF on neutrophil apoptosis and to inhibit GM-CSF-induced de novo protein synthesis. In contrast to GM-CSF, VAA-I does not induce tyrosine phosphorylation by itself and does not alter the GM-CSF-induced response. Among the inhibitors used, genistein, pertussis toxin, staurosporine, H7, Calphostin C, manoalide, BpB, quinacrine HA-1077, and z-VAD-FMK, only the latter (inhibitor of caspases-1, -3, -4, and -7) was found to inhibit VAA-I-induced neutrophil apoptosis as the percentage of apoptotic cells decrease from 98 +/- 1.3 to 54 +/- 3.2% (n=4). Furthermore, we confirm that caspases are involved in VAA-I-induced neutrophil apoptosis as we have observed the fragmentation of the cytoskeletal gelsolin protein that is known to be caspase-3-dependent. Such degradation was reversed by the z-VAD-FMK inhibitor. We conclude that induction of neutrophil apoptosis by VAA-I is a caspase-dependent mechanism that does not involve tyrosine phosphorylation events, G-proteins, PKCs, and PLA2. In addition, we conclude that at least caspase-3 is involved. Correlation between VAA-I-induced neutrophil apoptosis and VAA-I-induced inhibition of de novo protein synthesis is discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11129652

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  9 in total

1.  Anti-inflammatory effect of Viscum album agglutinin-I (VAA-I): induction of apoptosis in activated neutrophils and inhibition of lipopolysaccharide-induced neutrophilic inflammation in vivo.

Authors:  V Lavastre; H Cavalli; C Ratthe; D Girard
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

2.  Withaferin A Inhibits Neutrophil Adhesion, Migration, and Respiratory Burst and Promotes Timely Neutrophil Apoptosis.

Authors:  Rosemary L Bayless; M Katie Sheats; Samuel L Jones
Journal:  Front Vet Sci       Date:  2022-06-17

3.  The intriguing normal acute inflammatory response in mice lacking vimentin.

Authors:  E Moisan; S Chiasson; D Girard
Journal:  Clin Exp Immunol       Date:  2007-08-03       Impact factor: 4.330

4.  Evaluation of the in vitro and in vivo proinflammatory activities of gold (+) and gold (-) nanoparticles.

Authors:  Isabelle Durocher; Claudie Noël; Valérie Lavastre; Denis Girard
Journal:  Inflamm Res       Date:  2017-07-04       Impact factor: 4.575

5.  Human neutrophils are targets to paracoccin, a lectin expressed by Paracoccidioides brasiliensis.

Authors:  R Ricci-Azevedo; R A Gonçales; M C Roque-Barreira; D Girard
Journal:  Inflamm Res       Date:  2017-10-10       Impact factor: 4.575

6.  Activation of human neutrophils by the anti-inflammatory mediator Esenbeckia leiocarpa leads to atypical apoptosis.

Authors:  Rafael de Liz; Heros Horst; Moacir Geraldo Pizzolatti; Tânia Silvia Fröde; Denis Girard
Journal:  Mediators Inflamm       Date:  2012-05-08       Impact factor: 4.711

7.  Oncopharmacological Perspectives of a Plant Lectin (Viscum album Agglutinin-I): Overview of Recent Results from In vitro Experiments and In vivo Animal Models, and Their Possible Relevance for Clinical Applications.

Authors:  Tibor Hajtó; Katarina Hostanska; Timea Berki; László Pálinkás; Ferenc Boldizsár; Péter Németh
Journal:  Evid Based Complement Alternat Med       Date:  2005-01-28       Impact factor: 2.629

8.  Difficulties and perspectives of immunomodulatory therapy with mistletoe lectins and standardized mistletoe extracts in evidence-based medicine.

Authors:  Tibor Hajtó; Krisztina Fodor; Pál Perjési; Pèter Németh
Journal:  Evid Based Complement Alternat Med       Date:  2011-01-09       Impact factor: 2.629

9.  NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors.

Authors:  Patrick J Mansky; Dawn B Wallerstedt; Timothy S Sannes; Jamie Stagl; Laura Lee Johnson; Marc R Blackman; Jean L Grem; Sandra M Swain; Brian P Monahan
Journal:  Evid Based Complement Alternat Med       Date:  2013-10-27       Impact factor: 2.629

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.